FDA 510(k)

BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)

N.º K: K233986 · 2024-03-15

SolicitanteBecton, Dickinson and Company

Fecha de decisión2024-03-15

Código de productoLON

Comité asesorMI

DecisiónSubstantially Equivalent

Resumen del dispositivo

BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is Becton, Dickinson and Company. It received FDA 510(k) clearance on 2024-03-15 under 510(k) number K233986. The device is classified under product code LON. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Preguntas frecuentes

What is the BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)?

BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) is a medical device that received FDA 510(k) clearance on 2024-03-15. The listed applicant is Becton, Dickinson and Company. The 510(k) number is K233986.

When did BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) receive FDA 510(k) clearance?

BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) received FDA 510(k) clearance on 2024-03-15, under 510(k) number K233986.

Who is the listed applicant for BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)?

The FDA 510(k) record lists Becton, Dickinson and Company as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)?

The FDA product code for BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL) is LON.

Ensayos clínicos relacionados

Los registros relacionados se emparejan automáticamente mediante nombres, códigos de producto u otros metadatos. Un emparejamiento no establece una relación clínica, científica, corporativa o regulatoria verificada; revise las fuentes oficiales enlazadas.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Otros registros que enlistan a Becton, Dickinson and Company como solicitante

K262163BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth K260128BD Preset™ and BD A-Line™ Arterial Blood Collection Syringes K252506BD Vacutainer® Safety-Lok™ Blood Collection Set; BD Vacutainer® Safety-Lok™ Blood Collection Set with Pre-Attached Holder K252378BD® MiniDraw™ Capillary Blood Collection System with BD® MiniDraw™ SST™ Capillary Blood Collection Tube K260184Onclarity™ Self-Collection Kit K252040BD Vacutainer® Plasma Separator Tubes (PST™), BD Vacutainer® Sodium Heparin Blood Collection Tubes

Ver todos los 102 dispositivos →

Dispositivos relacionados (Código: LON)

K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc.K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)BIOMERIEUX K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc.K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company K250447BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)Becton, Dickinson and Company K234012VITEK COMPACT PRObioMerieux, Inc.

Fuente oficial

Ver en la base de datos de la FDA →

Datos procedentes de la API abierta de la FDA. Para obtener la información más actualizada y autoritativa, consulte siempre el registro oficial.